Tag Archives: NIH

ICAN SUES NIH

The Informed Consent Action Network (ICAN) has filed a lawsuit against the National Institutes of Health because NIH has not provided records responding to ICAN’s Freedom of Information Act (FOIA) requests related to the coronavirus pandemic. Now more than ever, it is imperative that regulatory agencies overseeing the healthcare industry are fully transparent with the public to ensure the true safety and efficacy of all products. #NIHFOIA #ICANvsNIH #ICAN #NIH #COVID19 #Moderna

 

00:00
Talking about our lawsuits about, I can decide org the informed consent action network.
00:06
Not only do we bring you this show.
Not only do we report on the mass casualties being caused by you know, miscalculations, perhaps even murdering people for political agendas or financial agendas or medical establishment agendas.
Somebody’S got to do something about it.
I mean, even if CNN got a story right, what do they do about it?
Well, here we do something different than anyone else can or does we do something about it, so I’m gonna bring you in a little earlier than I usually do.
Usually, I’m reporting to you about a lawsuit we just won.
I want to report to you about a lawsuit that we have just filed, and this is based on many of the lawsuits, we’ll the one with the wins against CDC, NIH Health and Human Services, the FDA.
00:49
They always start with Freedom, Information Act, requests, FOIA requests and the government has about 30 days to respond to our requests.
Sometimes they’ll even agree to fast-track it, which is what they said.
They would do with many of the requests that I’m going to have in this lawsuit, but it’s now been over three months and in the middle of these issues with a vaccine racing in here we deserve answers.
We want answers and we’re not going to let the natural Institute of Health or Tony Fauci and his double-talk get away from this one, and so we are filing we’ve just filed a lawsuit.
This week I mean you can find all this by the way you ever want to read our lawsuits or the wins that we’ve had good.
I can decide org and you can check them out, look at them under our lawsuits, but let me go ahead and show you what we’re demanding right now and see if you’re gonna look forward to our response.
This is the informed consent action network as a plaintiff against the National Institutes of Health.
Here’S what we’re asking for and further in furtherance of its mission and in order to respond to the inquiries it is received plaintiff made a number of requests to NIH pursuant to the Freedom of Information Act FOIA for documents regarding Coe bid 19 and a potential koban 19 vaccine, including a request for all safety and efficacy data and information regarding our mrna 1273, including from the phase 1 clinical trials of this experimental vaccine, while NIH granted expedited processing for this request.
Nih has failed to further to this and all the other related requests submitted by ICANN as required under FOIA.
So here’s what we’re looking for copies of any and all employee invention report related to that’s right, invention report related to any vaccine or therapeutic for cope in nineteen, copies of any and all royalty or licensing agreements related to any vaccine or therapeutic for code bid.
Nineteen remember this is all from the NIH a copy of the page of any patent application filed with regard to the MRNA 1273 vaccine, which lists the inventors we also want.
As of on April 10 2020, I can also made the following request to NIH all emails sent or received by Anthony pouchy between November 1st and 2019, the president that include the term moderna or mrna 1273 in any portion of the email, including the body.
03:05
Subject: metadata sender line a recipient line of the email or any attachment to the email.
The same day, I can made the same request as to Barney Gramm, for that’s FOIA request, five, three: nine two six, his Makia Corbett and Michael Gordon Joyce.
These are all scientists that hold patents for this vaccine inside of NIH.
Our own government agencies, our own scientists all have patents, Masuya Kenickie, oh you get.
03:31
The idea goes there.
It is there’s the patent there’s their names.
These people are going to make millions of dollars.
Yeah they work for the government they’re supposed to be objective yet are they pushing for their own vaccine?
We’Re gonna get to the bottom of this, and I made that here we go submitted a FOIA request to NIH for all safety and efficacy data information recording mrna 1273, including from the phase 1 clinical trial of this experimental vaccine conducted by the National Institute of Allergy and Infectious Disease Nyad, which is exactly where Tony pouch, is the head of Nyad.
04:05
You get the idea, we’re not playing games.
We are going to get answers.
We are crawling up your butt Tony because there’s too many lies and there are too many lives have been lost too many lives at stake and I’m tired of you living in the future and complaining about someone not using your imaginary vaccine.
I think you mental health issues, whatever the case and whatever these are just opinions of mine, but once we get the facts, maybe we will know who and how to sue.
If you want to help us with this process to make sure we’re getting real answers, not being sold a bill of goods and propaganda by people that stand to make millions of dollars, please support us.
I can decide org we’re asking you to give 20 for 20, 20 or whatever you can give on a recurring basis.
We are not playing around.
We are not going to go through an Independence Day and get through it and let our freedom be wiped out by liars and moron.
If you like that, clip then be sure to check out our live broadcast of the highwire every Thursday morning at 11.

 

Source:

The HighWire with Del Bigtree

Fair Use Notice: Images/logos/graphics on this page contains some copyrighted material whose use has not been authorized by the copyright owners. We believe that this not-for-profit, educational, and/or criticism or commentary use on the Web constitutes a fair use of the copyrighted material (as provided for in section 107 of the US Copyright Law).

Benefits of Early Antiretroviral Therapy in HIV Infection

AIDS is caused by HIV, a retrovirus that attacks the immune system. The virus destroys CD4+ T cells, a type of white blood cell that’s vital to fighting off infection. The number of these cells, known as a CD4+ count, is a key measure of immune system health. After people get infected with HIV, their immune system becomes progressively weaker from the HIV infection, their CD4+ count drops, and eventually they develop AIDS.

AIDS is treated with antiretroviral drugs. These drugs suppress HIV but don’t completely eliminate the virus from the body. Guidelines for when to start treatment differ around the world because the evidence for using antiretroviral drugs when CD4+ counts are higher wasn’t definitive. Some experts felt it prudent to wait until the disease progressed to CD4+ levels at which there was a proven benefit.

The START (Strategic Timing of AntiRetroviral Treatment) study is a randomized, controlled clinical trial designed to more clearly define the optimal time for people with HIV to begin antiretroviral therapy. The study was funded in part by NIH’s National Institute of Allergy and Infectious Diseases (NIAID) and other NIH components.

Researchers in 215 clinics across 35 countries enrolled 4,685 HIV-positive men and women ages 18 and older. All participants had CD4+ counts in the normal range (above 500 cells/mm3) at the time of enrollment and had never taken antiretroviral therapy. They were randomly assigned to 2 groups. The early-treatment group began taking antiretrovirals immediately. The deferral group delayed treatment until their CD4+ counts dropped to 350 cells/mm3 or until they developed AIDS or another condition that required antiretroviral treatment.

The team tracked combinations of outcomes: serious AIDS events (such as AIDS-related cancers or death from AIDS) and serious non-AIDS events (such as cardiovascular disease, end-stage renal disease, liver disease, and non-AIDS-related death).

In May 2015, an independent panel reviewed interim results. They found that the benefits of early antiretroviral therapy far outweighed any risks. The findings were disseminated to study participants, and treatment was offered to everyone in the deferred group.

The research team reported additional findings online on July 20, 2015, in the New England Journal of Medicine. The scientists determined that the overall risk of developing serious AIDS-related events, serious non-AIDS events, or death was reduced by 57% among those in the early-treatment group compared to those in the deferred group. This reduction was seen regardless of age, sex, baseline CD4+ counts, geographic region, or country income level.

Early antiretroviral treatment lowered the risk of serious AIDS-related events by 72%. Early treatment also lessened the risk of serious non-AIDS events by 39%.

A limitation of the study, the researchers note, is that the participants were fairly young, with a median age of 36 years. In addition, they were only followed for 3 years, which is fairly short given that antiretroviral therapy is typically prescribed for a lifetime.

“This study conclusively shows that the benefits of early therapy far outweigh any adverse outcomes, and reinforces recommendations to offer immediate antiretroviral therapy to all HIV patients,” says NIAID Director Dr. Anthony S. Fauci.

Source: FDA.Gov